Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Corbus Pharmaceuticals (CRBP)
NASDAQ:CRBP
Holding CRBP?
Track your performance easily
CRBP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.03 - $61.90
Previous Close$18.78
Volume266.08K
Average Volume (3M)653.70K
Market Cap
$223.05M
Enterprise Value$67.30M
Total Cash (Recent Filing)$159.36M
Total Debt (Recent Filing)$3.61M
Price to Earnings (P/E)―
Beta2.38
Next Earnings
Mar 18, 2025EPS Estimate
-$1.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.70
Shares Outstanding12,043,940
10 Day Avg. Volume354,406
30 Day Avg. Volume653,703
Standard Deviation0.55
R-Squared0.06
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)1.80
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.60
Forecast
1Y Price Target
$69.80Price Target Upside271.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Corbus Pharmaceuticals News
PremiumCompany Announcements
Corbus Pharmaceuticals Reports Q3 2024 Financials and Updates
PremiumCompany Announcements
Corbus Pharmaceuticals Reports Q3 2024 Financial ResultsBulls Say, Bears Say
Bulls Say
Drug Development And SafetyCRB-913 demonstrated a unique pharmacokinetic profile with significantly lower brain exposure, suggesting a potentially improved safety profile.
Investment PotentialDespite recent share weakness due to concerns about CRBP's obesity asset, the main focus for CRBP is on the oncology asset '701, which has favorable risk/reward prospects.
Oncology TreatmentCRB-701 is designed to target Nectin-4 with improved safety and tolerability compared to standard treatments for bladder and cervical cancers.
Bears Say
Adverse EventsThe imbalance and dose dependency in neuropsychiatric adverse events seen in the treatment arm were the main cause for concern among investors.
Clinical Trial ResultsRecent share weakness primarily reflects uncertainty with CRBP's obesity asset, CRB-913, leading to a significant drop in share value.
Market ExpectationsNovo may have overpromised on weight loss, leading the market to perceive a 6% reduction in weight at 16 weeks as falling short of the expectations.
---
Ownership Overview
31.44% Insiders
8.20% Mutual Funds
1.85% Other Institutional Investors
44.17% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRBP FAQ
What was Corbus Pharmaceuticals’s price range in the past 12 months?
Corbus Pharmaceuticals lowest stock price was $3.03 and its highest was $61.90 in the past 12 months.
What is Corbus Pharmaceuticals’s market cap?
Currently, no data Available
When is Corbus Pharmaceuticals’s upcoming earnings report date?
Corbus Pharmaceuticals’s upcoming earnings report date is Mar 18, 2025 which is in 129 days.
How were Corbus Pharmaceuticals’s earnings last quarter?
Corbus Pharmaceuticals released its earnings results on Nov 07, 2024. The company reported -$1.15 earnings per share for the quarter, missing the consensus estimate of -$0.952 by -$0.198.
Is Corbus Pharmaceuticals overvalued?
According to Wall Street analysts Corbus Pharmaceuticals’s price is currently Undervalued.
Does Corbus Pharmaceuticals pay dividends?
Corbus Pharmaceuticals does not currently pay dividends.
What is Corbus Pharmaceuticals’s EPS estimate?
Corbus Pharmaceuticals’s EPS estimate is -$1.18.
How many shares outstanding does Corbus Pharmaceuticals have?
Corbus Pharmaceuticals has 12,043,940 shares outstanding.
What happened to Corbus Pharmaceuticals’s price movement after its last earnings report?
Corbus Pharmaceuticals reported an EPS of -$1.15 in its last earnings report, missing expectations of -$0.952. Following the earnings report the stock price went down -2.062%.
Which hedge fund is a major shareholder of Corbus Pharmaceuticals?
Among the largest hedge funds holding Corbus Pharmaceuticals’s share is Woodline Partners LP. It holds Corbus Pharmaceuticals’s shares valued at 11M.
---
Corbus Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$69.80 (271.67% Upside)
$69.80 (271.67% Upside)
Blogger Sentiment
Bullish
CRBP Sentiment 75%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 263.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $7.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.9%
Last 30 Days ▲ 6.7%
Last 30 Days ▲ 6.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
391.62%
12-Months-Change
Fundamentals
Return on Equity
-51.32%
Trailing 12-Months
Asset Growth
352.47%
Trailing 12-Months
Company Description
Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.
---
CRBP Stock 12 Month Forecast
Average Price Target
$69.80
▲(271.67% Upside)
Technical Analysis
PAVmed
―
Cyclacel Pharmaceuticals
―
Karyopharm Therapeutics
―
TRACON Pharmaceuticals
―
Best Analysts Covering CRBP
1 Year
1 Year Success Rate
4/10 ratings generated profit
1 Year Average Return
+7.66%
reiterated a buy rating 3 days ago
Copying Jeff Jones's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +7.66% per trade.
---